As real-world data (RWD) becomes central to modern regulatory and clinical decision-making, the challenge for sponsors lies in transforming messy, incomplete datasets into reliable, regulatory-grade evidence.

This case study showcases how MMS Holdings leveraged its advanced KerusCloud® simulation platform to design and validate a study that integrated RWD with clinical trial insights helping a global sponsor demonstrate treatment effectiveness, reduce risk, and strengthen their submission strategy.

Whether you’re leading clinical operations, regulatory strategy, or data science, this resource demonstrates how simulation-driven study design can turn uncertainty into confidence ensuring data accuracy, patient safety, and faster approvals.

Key Benefits / What You’ll Learn:

• Discover how KerusCloud® generates virtual patient populations to test and optimize trial designs before execution.
• Learn how integrating RWD improved statistical power and increased evidence credibility.
• Understand how simulation can reduce data variability and accelerate time to regulatory submission.
• Explore how MMS helped the sponsor align RWD-driven insights with evolving FDA and EMA guidance.
• Gain a clear picture of how simulation-based design strengthens the evidence base for clinical and post-marketing studies.

Created by MMS data science and biostatistics experts, trusted globally for designing data-driven studies that support faster, smarter regulatory and development decisions.